Live Breaking News & Updates on கண்டுபிடிப்பு வளர்ச்சி ஜெநரேஶந் செயல்திறன்

Stay updated with breaking news from கண்டுபிடிப்பு வளர்ச்சி ஜெநரேஶந் செயல்திறன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Evotec launches 'beLAB1407' to accelerate translational research from the UK's academic life science

Search jobs
06-May-2021
Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science ecosystem in collaboration with Bristol Myers Squibb
DGAP-News: Evotec SE
/ Key word(s): Miscellaneous
06.05.2021 / 07:30
beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
THE COLLABORATION LEVERAGES EVOTEC S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR
Hamburg, Germany, 06 May 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportuniti ....

United States , United Kingdom , City Of , Great Britain , Andrew Naylor , George Baxter , Werner Lanthaler , David Mcbeth , Thomas Hanke , Volker Braun , Rupert Vessey , David Coleman , Gabriele Hansen , Innovation Development Generation Efficiency , University Of Birmingham Enterprise , Boehringer Ingelheim , University Of Birmingham , Bristol Myers Squibb Company , Distribution Services , University Of Edinburgh , Exonate Ltd , Nottingham Technology Ventures , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Biomedical Research , University Of Dundee ,

Partnership launched to fast track drug discovery

Date Time
Partnership launched to fast track drug discovery
The University of Nottingham is part of a new industry collaboration launched to accelerate drug discovery projects that will fast track research from lab to patient.
The University of Nottingham is one of four universities selected by drug development company Evotec SE and global pharmaceutical company Bristol Myers Squibb to be part of the newly formed beLAB1407.
Evotec, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Nottingham, Birmingham, Edinburgh and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the crea ....

United States , United Kingdom , City Of , Great Britain , Rupert Vessey , Werner Lanthaler , Innovation Development Generation Efficiency , University Of Nottingham , Bristol Myers Squibb Company , Exonate Ltd , Early Development At Bristol Myers Squibb , Oncimmune Plc , Scancell Plc , Life Sciences , Bristol Myers Squibb , Biomedical Research , Development Generation Efficiency , United Kingdom Universities , Bristol Myers Squib , Chief Executive Officer , Executive Vice President , Early Development , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , நன்று பிரிட்டன் ,

Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb

Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Baden Wüberg , United States , Peter Grathwohl , Rhein Neckar , Manfred Schubert Zsilavecz , Werner Lanthaler , Thomas Hanke , Matthias Hentze , Volker Braun , Rainer Wessel , Rupert Vessey , Matthias Weidem , Gabriele Hansen , Innovation Development Generation Efficiency , Boehringer Ingelheim , Bristol Myers Squibb Company , Third Mission , German Cancer Research Center , Innovation Of The University , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Heidelberg University , Biomedical Research , Goethe University Frankfurt , European Molecular Biology Laboratory , Evotec Se Frankfurt Stock Exchange ,

Evotec launches 'beLAB2122', translating academic innovation from leading German life science region

Evotec launches 'beLAB2122', translating academic innovation from leading German life science region
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Baden Wüberg , United States , Peter Grathwohl , Rhein Neckar , Manfred Schubert Zsilavecz , Werner Lanthaler , Thomas Hanke , Matthias Hentze , Volker Braun , Rainer Wessel , Rupert Vessey , Matthias Weidem , Gabriele Hansen , Innovation Development Generation Efficiency , Boehringer Ingelheim , Bristol Myers Squibb Company , Third Mission , Distribution Services , German Cancer Research Center , Innovation Of The University , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Heidelberg University , Biomedical Research , Goethe University Frankfurt , European Molecular Biology Laboratory ,

Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb

Published: Apr 13, 2021
beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY
EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ
BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122
HAMBURG, GERMANY /
/ April 13, 2021 /
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. ....

Baden Wuberg , United States , Peter Grathwohl , Rhein Neckar , Manfred Schubert Zsilavecz , Werner Lanthaler , Thomas Hanke , Matthias Hentze , Volker Braun , Rainer Wessel , Rupert Vessey , Matthias Weidem , Gabriele Hansen , Innovation Development Generation Efficiency , Boehringer Ingelheim , Bristol Myers Squibb Company , Third Mission , German Cancer Research Center , Innovation Of The University , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Heidelberg University , Biomedical Research , Goethe University Frankfurt , European Molecular Biology Laboratory , Evotec Se Frankfurt Stock Exchange ,